(Q45960014)

18 December 2017

title

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. (English)

1 reference

18 December 2017

author

William Janssen

8

1 reference

18 December 2017

author name string

T Field

1

1 reference

18 December 2017

J Perkins

2

1 reference

18 December 2017

Y Huang

3

1 reference

18 December 2017

M A Kharfan-Dabaja

4

1 reference

18 December 2017

M Alsina

5

1 reference

18 December 2017

E Ayala

6

1 reference

18 December 2017

H F Fernandez

7

1 reference

18 December 2017

J Lancet

9

1 reference

18 December 2017

L Perez

10

1 reference

18 December 2017

D Sullivan

11

1 reference

18 December 2017

A List

12

1 reference

18 December 2017

C Anasetti

13

1 reference

18 December 2017

language of work or name

English

0 references

publication date

22 June 2009

1 reference

18 December 2017

Bone Marrow Transplantation

published in

1 reference

18 December 2017

volume

45

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

255-260

1 reference

18 December 2017

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

A Proportional Hazards Model for the Subdistribution of a Competing Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

inferred from DOI database lookup

7 January 2021

based on heuristic

Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

inferred from DOI database lookup

7 January 2021

based on heuristic

Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.134

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/BMT.2009.134

1 reference

18 December 2017

Dimensions Publication ID

1022244238

0 references

1 reference

18 December 2017